Annexon (ANNX)
(Delayed Data from NSDQ)
$4.49 USD
-0.31 (-6.36%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $4.50 +0.01 (0.22%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ANNX 4.49 -0.31(-6.36%)
Will ANNX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ANNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANNX
Are Medical Stocks Lagging Annexon (ANNX) This Year?
Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now
ANNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet
Other News for ANNX
Annexon spikes after updating late-stage results for lead asset against GBS
Annexon Biosciences (ANNX) Gets a Buy from TD Cowen
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
Annexon reports additional 'positive' Phase 3 results for ANX005
Small-cap, buy-rated stocks with positive estimate revision factors - BofA